Clinical research of the malignant hydrothorax or hydroperitoneum treated with intracavitary chemotherapy and local thermotherapy

• DOI: 10.1200/jco.2007.25.18_suppl.19615
• Publication Date: 2020-03-06T21:16:25Z
• Authors: H. Song; l. Chen; J. Wang; X. Chu; Q. Zhang; H. Geng
• Keywords: Hydrothorax

19615 Background: Malignant hydrothorax or hydroperitoneum are common complications of the cancer. Pure chemotherapy couldn’t get good effect. We combined intracavitary with local thermotherapy to cure malignant hydroperitoneum. In order observe recent effects and toxicity thermochemotherapy evaluate change immunologic function, investigate mechanism thermochemotherapy. Methods: Fifty-two patients were treated weekly chemotherapy, then twice a week. As control, another fifty received chemotherapy. Treated for two weeks rest one week, observed toxicity. Test level T cell subset, NK cells VEGF in serum effusion Results: Overall response rate was 86.9% vs 60.0% (P<0.05), 79.3% 46.7% (P <0.01).The incidence myelosuppression 7.7% 24% (P<0.05). After thermochemotherapy, ratio CD4/CD8 rose significantly (P<0.01), but decreased (P<0.05) While peripheral blood, all CD3, CD4, CD8, Meanwhile whether blood. Conclusions: Combined could control effectively less-toxicity. The cellular immune function elevated neovascularization tumor probablely inhibited. No significant financial relationships disclose.